Cumulative Index 1977

ABDOMINAL PLAIN FILM EXAMINATION, in diagnosis of adrenal lesions, June, 305
ACTH, Cushing's syndrome and, June, 212–213
synthesis and release of, June, 182–184
ACTH stimulation, exogenous, in Cushing's syndrome, June, 218
Actinomycin D, in treatment of nonseminomatous testicular tumors, Oct., 474, 475
Adenocarcinoma, testicular. See *Yolk sac tumor.*
Adenoma, adrenal, pathologic findings in, June, 234
adrenal cortical, radiologic studies in, June, 310
treatment of, June, 220
aldosterone-producing, diagnosis in, June, 232
treatment in, June, 235
cystic, of adrenal gland, pathologic features of, June, 274
Adrenal androgen secretion, June, 185–186
Adrenal cortex, embryologic development of, June, 169
Adrenal cortical carcinoma, pathologic findings in, June, 234
Adrenal cortical disease, medical management of, June, 297–304
pharmacopathology of, June, 297–299
Adrenal cysts. See *Cysts, adrenal.*
Adrenal ectopia, sites of, June, 170
Adrenal glands, accessory, sites of, June, 170
anatomy of, June, 169–177
blood supply to, June, 171
embryologic development of, June, 169–171
clinical and surgical implications of, June, 170–171
histologic anatomy of, June, 174–176
innervation of, anatomy of, June, 173
physiology and pharmacology of, June, 179–192
surgery in, June, 327–336
Adrenal glands (*Continued*)
Surgery in, complications of, June, 334–335
technical considerations in, June, 330–331
techniques of, June, 331–334
Adrenal hyperplasia, congenital, classification and management of, June, 193–209
Adrenal insufficiency, as complication of adrenal surgery, June, 335
Adrenal medulla, embryologic development of, June, 170
nonfunctioning tumors of, June, 265–269
Adrenal paraganglionic system, embryologic development of, June, 170
Adrenal steroidogenesis, mechanism of, June, 193–195
Adrenal tumors. See *Tumors, adrenal* and specific tumors.
Adrenalectomy, in Cushing's disease, June, 223
in management of Bartter's syndrome, June, 257
Adrenocortical tumors, Cushing's syndrome and, June, 211–212
nonfunctioning, clinical features of, June, 263
surgical indications and contraindications in, June, 328
Adrenocorticotrophic hormone, Cushing's syndrome and, June, 212–213
synthesis and release of, June, 182–184
Adrenogenital syndrome, nonfunctioning adrenal tumors and, June, 263
radiologic studies in, June, 315
surgical indications and contraindications in, June, 323–329
Adrenergic blockade, alpha, in management of pheochromocytoma, June, 240–241
beta, in management of pheochromocytoma, June, 241
Adrenergic receptors, classification of, June, 190–191
Aldosterone, action of, June, 186

Aldosterone (*Continued*)
measurement of, June, 231–233
secretion of, control of, June, 187
Aldosterone-producing adenoma, diagnosis in, June, 232
treatment in, June, 235
Aldosteronism, primary. See *Primary aldosteronism.*
secondary, Bartter's syndrome and, June, 256
Aldosteronoma, radiologic studies in, June, 311
Alpha-adrenergic blockade, in management of pheochromocytoma, June, 240–241
Alpha-fetoprotein, detection of, in yolk sac tumors, Oct., 372, 373
elevated levels of, in seminoma, Oct., 400, 401
Alpha-fetoprotein, in treatment planning of nonseminomatous germ cell testicular cancer, Oct., 534
serum levels of, in treatment of patients with testicular tumors, Oct., 393–406
Amine precursor uptake and decarboxylation cells, pheochromocytoma and, June, 239
Androgen secretion, adrenal, June, 185–186
Δ^4 Androstenedione, secretion of, June, 186
Anesthesia, administration of, in surgical management of pheochromocytoma, June, 244–245
in adrenal surgery, June, 319–326
Animal models, studies of testicular tumors in, Oct., 496–500
Angiography, in preoperative localization of pheochromocytoma, June, 241–242
Angiomatous cysts, of adrenal gland, pathologic features of, June, 275
Angiotensin, generation of, June, 186–187
Anomalies, of adrenal gland, surgical implications of, June, 171
Antigens, immunology of adrenal neuroblastoma and, June, 292
Aortography, in localization of pheochromocytoma, June, 241
APUD cells, pheochromocytoma and, June, 239
Arteries, adrenal, surgical anatomy of, June, 171
Arteriography, in diagnosis of adrenal cysts, June, 276
in diagnosis of adrenal lesions, June, 307
in primary aldosteronism, June, 233
renal, pentrating injuries and, Feb., 5, 30, 31
Artery(ies), renal, thrombosis of, Feb., 13–16

BACILLUS CALMETTE-GUÉRIN IMMUNOTHERAPY, in treatment of disseminated testicular carcinoma, Oct., 417
Bartter's syndrome, biochemical abnormalities in, June, 254–255
pathogenesis and management of, June, 253–261
pathologic abnormalities in, June, 254
physiologic abnormalities and, June, 256
Bartter's syndrome (*Continued*)
secondary aldosteronism and, June, 256
surgical indications and contraindications in, June, 329
Beta adrenergic blockade, in management of pheochromocytoma, June, 241
Biochemical studies, in diagnosis of adrenal cysts, June, 278
Biopsy, aspiration, in evaluation of testicular mass, Oct., 435
Bladder, urinary, pheochromocytoma of, June, 244
flap, ureteral injury and, Feb., 51–57
injuries to, Feb., 59–67
neck, injury to, Feb., 113, 114
Bleomycin, in treatment of disseminated testicular carcinoma, Oct., 416
Blockade, pharmacologic, in management of pheochromocytoma, June, 240–241
Buccal smear, in diagnosis of 21-hydroxylase deficiency, June, 199
Burns, genital trauma and, Feb., 153–155

CALCIFICATION, in adrenal carcinoma, June, 305
Carcinoma, adrenal, treatment of, June, 221
adrenocortical, laboratory findings in, June, 264
pathologic findings in, June, 234, 264
signs and symptoms of, June, 263
treatment in, June, 265
embryonal cell, in children, management of, Oct., 349, 350
testicular. See also *Testicular carcinoma.*
disseminated, chemotherapy for, Oct., 407–426
management of patients with, Oct., 427–451
Cardiovascular crises, as complication of adrenal surgery, June, 335
Catecholamines, adrenal, actions of, June, 190–191
biosynthesis of, June, 189–190
Catheterization, urethral injury and Feb., 84, 85
Cell lines, of human testicular cancer, culture of, Oct., 529–536
Central nervous system, response of, to corticosteroid therapy, in adrenal cortical disease, June, 302
Chemotherapy, for disseminated testicular carcinoma, Oct., 407–426
for nonseminomatous germ cell testicular carcinoma, Oct., 489, 490
effects of, Oct., 473, 474
in adrenal neuroblastoma, June, 291
in adrenocortical carcinoma, June, 265
in human testicular tumors, testing of, Oct., 535
in management of testicular tumors, in children, Oct., 356
preoperative, in advanced nonseminomatous testicular tumors, Oct., 467
Children, testicular tumors in, classification and treatment of, Oct., 347–358

Children (*Continued*)
management of, Oct., 443–445
Cholesterol, conversion of, to pregnenolone, June, 180
Choriocarcinoma, management of, in children, Oct., 350
pathology of, Oct., 369–371
Chromaffin tissue, extramedullary, surgical implications of, June, 171
Cis-platinum, in treatment of disseminated testicular carcinoma, Oct., 416
Clitoral enlargement, fetal virilization and, June, 197–198
Clitoridectomy, in 21-hydroxylase deficiency, June, 204
Clitoroplasty, reductive, in 21-hydroxylase deficiency, June, 204–205
Complications, renal trauma and, Feb., 26, 27
Computerized axial tomography, in diagnosis of adrenal lesions, June, 308–309
Congenital adrenal hyperplasia, classification and management of, June, 193–209
Conn's syndrome, nonfunctioning adrenal tumors and, June, 263
Cortex, adrenal, disease of, medical management of, June, 297–304
embryologic development of, June, 169
functional zonation of, June, 180–182
histologic anatomy of, June, 175
physiology and pharmacology of, June, 179–188
Cortical tissue, adrenal, accessory, sites of occurrence of, June, 170–171
Corticosteroid therapy, in adrenal cortical disease, June, 299–303
Corticotrophin releasing factor, function of, June, 182–184
Cortisol, overproduction of, adrenal cortical disease and, June, 298–299
Cushing's syndrome and, June, 211
secretion of, June, 184, 185
control of, June, 182–186
underproduction of, in adrenal cortical disease, June, 298
Cortisol therapy, in 21-hydroxylase deficiency, June, 203
Cushing's syndrome, adrenal cortical disease and, June, 298, 299
clinical features of, June, 213–215
etiology and management of, June, 211–226
diagnosis of, June, 215–220
nonfunctioning adrenal tumors and, June, 263
radiologic studies in, June, 309–310
surgical indications and contraindications in, June, 327, 328
surgical management of, anesthesia in, June, 322–323
treatment of, June, 220–224
Cyproheptadine therapy, in Cushing's disease, June, 222
Cystic adenomas, of adrenal gland, pathologic features of, June, 274
Cysts, adrenal, clinical features of, June, 275, 276
Cysts (*Continued*)
adrenal, diagnosis and treatment of, June 273–283
surgical indications and contraindications in, June, 329

DEHYDROEPIANDROSTERONE, secretion of, June, 186
Desmolase deficiency, clinical features of, June, 207
Dexamethasone suppression test, high dose, Cushing's syndrome and, June, 217, 218
low dose, Cushing's syndrome and, June, 217
Disseminated testicular carcinoma, chemotherapy for, Oct., 407–426
Diuretic therapy, in primary aldosteronism, June, 235

"ECTOPIC ACTH SYNDROME," Cushing's syndrome and, June, 212
treatment of, June, 221
Endothelial cysts, of adrenal gland, pathologic features of, June, 275
Ejaculation, physiology of, Oct., 524, 525
Embryonal cell carcinoma, cells of, culture of, Oct., 530, 531
histologic characteristics of, Oct., 499, 500
in children, management of, Oct., 349, 350
pathology of, Oct., 365–367
Endodermal sinus tumor. See *Yolk sac tumor.*
Epithelial cysts, of adrenal gland, pathologic features of, June, 274
Erectile ability, after retroperitoneal lymphadenectomy, Oct., 523, 524
Erythrocyte sodium transport, disorders of, Bartter's syndrome and, June, 254
Erythropoietin, excessive production of, Bartter's syndrome and, June, 255
Eye, in corticosteroid therapy, in adrenal cortical disease, June, 302

FERTILITY, effect of retroperitoneal lymphadenectomy on, Oct., 445, 523, 524
Fistula, urethral, Feb., 122
Flap(s), bladder, ureteral injury and, Feb., 51–57
genital reconstruction and, Feb., 135
renal capsule, ureteral injury and, Feb., 45–49
Fractures, of pelvis, urethral injuries and, Feb., 81–93

GANGLIONEUROBLASTOMAS, of adrenal medulla, pathogenesis and treatment of, June, 265–269

Ganglioneuroma, of adrenal gland, surgical indications and contraindications in, June, 329
of adrenal medulla, pathogenesis and treatment of, June, 265–269
Gastrointestinal tract, in corticosteroid therapy, in adrenal cortical disease, June, 302
Genitalia, ambiguous, classification of, June, 197, 198
external, development of, June, 195, 196
initial management of injuries to, Feb., 143–156
secondary reconstruction of, Feb., 133–141, 157–162
Genitourinary disease, specificity of elevated alpha-fetoprotein and human chorionic gonadotropin levels in patients with, Oct., 396, 397
Germinal cell testicular tumors, culture of, Oct., 530, 531
histogenesis of, Oct., 503, 504
in infants and children, management of, Oct., 349, 350
pathology of, Oct., 359–378
Glucocorticoid therapy, in 21-hydroxylase deficiency, June, 201–204
Glucocorticoids, adrenal, secretion of, control of, June, 182–186
Grafts, genital reconstruction and, Feb., 135–140
Groin dissection, radical, in management of testicular masses, Oct., 438

HAMARTOMAS, of adrenal gland, diagnosis and treatment of, June, 269
Hematoma, pelvic, Feb., 86, 87
Hemorrhage, adrenal, as surgical complication, June, 334
in neonates, surgical indications and contraindications in, June, 329
surgical implications of, June, 171
pelvic fracture and, Feb., 86, 87
retroperitoneal, following orchiectomy, Oct., 447, 448
Herpesviruses, DNA-containing, role of, in human cancers, Oct., 534
Human chorionic gonadotropin, in treatment planning of nonseminomatous germ cell testicular cancer, Oct., 534
radioimmunoassay of, in management of choriocarcinoma, Oct., 370, 371
serum levels of, measurement of, in treatment of patients with testicular tumors, Oct., 393–406
Human testicular cells, in culture, Oct., 529–536
Hydrocortisone therapy, in 21-hydroxylase deficiency, June, 203
18-Hydroxydehydrogenase deficiency, clinical features of, June, 207
11-β-Hydroxylase deficiency, clinical features of, June, 206
17-Hydroxylase deficiency, clinical features of, June, 207
18-Hydroxylase deficiency, clinical features of, June, 207
21-Hydroxylase deficiency, diagnosis and management of, June, 196–205
laboratory findings in, June, 201
3-β-Hydroxysteroid dehydrogenase deficiency, clinical features of, June, 206, 207
Hyperadrenocorticism, as complication of adrenal surgery, June, 335
Hyperaldosteronism, adrenal cortical disease and, June, 299
nonfunctioning adrenal tumors and, June, 263
Hypercortisolism, clinical features of, June, 213–215
Hyperglycemia, corticosteroid therapy and, June, 302
Hypertension, idiopathic, surgical indications and contraindications in, June, 330
in patients with Cushing's syndrome, June, 215
in patients with pheochromocytoma, June, 247
primary aldosteronism and, June, 228
Hypomagnesemia, Bartter's syndrome and, June, 255
Hypothalamic-pituitary-adrenal axis, function of, June, 182
response of, to corticosteroid therapy, June, 299–301
Hypovolemia, Bartter's syndrome and, June, 256

IDIOPATHIC HYPERALDOSTERONISM, diagnosis in, June, 232
Immunobiology, of testicular tumors, Oct., 501, 502
Immunologic studies, in human testicular tumors, Oct., 534
Immunology, in management of adrenal neuroblastoma, June, 291, 292
Immunotherapy, bacillus Calmette-Guérin, in treatment of disseminated testicular carcinoma, Oct., 417
Impotence, urethral stricture and, Feb., 123
Infantilism, sexual, etiology of, June, 207
Infants, testicular tumors in, classification and treatment of, Oct., 347–358
Infection, of inguinal or scrotal incision, management of, Oct., 448
Injuries, peritoneal, as complication of adrenal surgery, June, 334
visceral, as complication of adrenal surgery, June, 334, 335
Interstitial cell tumors, in children, management of, Oct., 351
Intravenous pyelography, penetrating renal injuries and, Feb., 4, 5, 24, 47, 48, 52, 54, 56
^{131}I–19-iodocholesterol scanning, in diagnosis of adrenal lesions, June, 308
Irradiation therapy, in Cushing's disease, June, 222

JUXTAGLOMERULAR CELLS, action of, June, 186

833K, development and culture of, Oct., 532, 533
Kallikrein, urinary, Bartter's syndrome and, June, 255
Kidney, autotransplantation, ureteral injury and, Feb., 43, 44
defects of, Bartter's syndrome and, June, 253
injuries to, blunt, Feb., 17–28, 29–32
penetrating, Feb., 3–12

LASIX-MANNITOL PROTOCOL, for intraoperative diuresis, Oct., 454, 455
Leydig cells, role of, in development of genitalia, June, 195
Lymph fistulas, persistent, management of, Oct., 448, 449
Lymphadenectomy, retroperitoneal, anterior approach, technique of, Oct., 509–521
effect of, on fertility, Oct., 445
in management of testicular tumors, in children, Oct., 352
sexual function after, Oct., 523–528
Lymphangiography, in diagnosis of nonseminomatous germ cell carcinoma, Oct., 480, 481
reaction to, surgical problems posed by, Oct., 446, 447
Lymphangiomatous cysts, of adrenal glands, pathologic features of, June, 275

MACRONODULAR HYPERPLASIA, adrenalectomy in, June, 223
Medulla, adrenal, embryologic development of, June, 170
histologic anatomy of, June, 176
nonfunctioning tumors of, June, 265–269
physiology and pharmacology of, June, 188–191
Metabolic reaction to corticosteroid therapy in adrenal cortical disease, June, 302
Metastases, of seminomas, patterns of spread of, Oct., 384
of testicular tumors, patterns of spread and histology of, Oct., 373, 374
Metyrapone test, in diagnosis of Cushing's syndrome, June, 218
Micronodular adrenal disease, adrenalectomy in, June, 223
Mineralocorticoid therapy, in 21-hydroxylase deficiency, June, 201–204
Mineralocorticoids, secretion of, regulation of, June, 186–187
Mitotane therapy, in Cushing's disease, June, 222
Musculoskeletal reactions, to corticosteroid therapy, in adrenal cortical disease, June, 302
Myelolipomas, of adrenal gland, diagnosis and treatment of, June, 269

NEOPLASMS. See *Tumors* and specific neoplasms.
Nephrostomy, drainage, ureteral injury and, Feb., 44
Nephrotomography, in diagnosis of adrenal lesions, June, 306
Nerves, of adrenal gland, anatomy of, June, 173
Neuroblastoma, adrenal, chemotherapy in, June, 291
clinical manifestations of, June, 288–289
diagnosis of, June, 289, 290
histologic features of, June, 285, 286
immunology in, June, 291, 292
radiation therapy in, June, 290
radiologic studies in, June, 315
staging of, June, 287
surgical indications and contraindications in, June, 329
surgical management in, June, 290
anesthesia in, June, 325, 326
of adrenal medulla, pathogenesis and treatment of, June, 265–269
Nongerminal cell testicular tumors, culture of, Oct., 530
in infants and children, management of, Oct., 350, 351
Nonseminomatous germ cell testicular carcinoma, diagnosis of, Oct., 479–482
radiation therapy for, in adults, Oct., 477–493
surgical treatment of, in adults, Oct., 453–463
treatment of, Oct., 482–489
Nonseminomatous testicular tumors, advanced, surgical management of, Oct., 465–476

OLIGOMENORRHEA, in cushingoid females, June, 215
Oncornaviruses, role of, in human cancers, Oct., 533, 534
Orchidocelioplasty, development of testicular tumor after, Oct., 441
Orchiectomy, and primary radiotherapy, results of, Oct., 486, 487
and retroperitoneal lymphadenectomy, and radiation, results of, Oct., 488
high inguinal, technique of, Oct., 434, 435
improper, problems resulting from, Oct., 436–439
in management of testicular tumors, in children, technique of, Oct., 352–356
retroperitoneal hemorrhage following, Oct., 447, 448
Orchioblastoma. See *Yolk sac tumor*.
Orchiopexy, development of testicular tumor after, Oct., 440
Organ of Zuckerkandl, embryologic development of, June, 170
Osteoporosis, corticosteroid therapy and, June, 302

PANCREAS, kidney and, injury to, Feb., 10, 11
Paraganglionic system, adrenal, development of, June, 170
Parasitic cysts, of adrenal gland, pathologic features of, June, 274
Pelvis, fracture of, urethral injuries and, Feb., 81–93
Penis, trauma to, Feb., 125–127, 133–141, 143–156, 157–162
Perineum, injury to, tissue loss and, Feb., 93
Pharmacologic blockade, in management of pheochromocytoma, June, 240, 241
Phenylethanolamine, action of, June, 190
Pheochromocytoma, determination of malignant process in, June, 246
  diagnosis and management of, June, 239–252
  long term follow-up in, June, 251
  malignant, functional aspects of, June, 247, 248
    incidence of, June, 246, 247
    prognosis and management of, June, 249–251
  metastatic, roentgenographic features of, June, 248
  of urinary bladder, June, 244
  postoperative care of, June, 251
  preoperative localization of, June, 241–243
  radiologic studies in, June, 312–315
  surgical exploration in, June, 245, 246
  surgical indications and contraindications in, June, 329
  surgical management of, anesthesia in, June, 244, 245, 323–325
Pituitary destruction therapy, in Cushing's disease, June, 222
Plasma bradykinin concentration, Bartter's syndrome and, June, 255
Plasma 17-hydroxyprogesterone concentration, in 21-hydroxylase deficiency, June, 199
Plasma renin activity, assessment of, in primary aldosteronism, June, 230, 231
Pneumography, retroperitoneal, in diagnosis of adrenal lesions, June, 306
Polyorchidism, testicular tumors associated with, Oct., 441
Primary aldosteronism, clinical and laboratory features in, June, 228–230
  diagnosis in, June, 230–234
  pathologic findings in, June, 234, 235
  radiologic examination in, June, 233, 234, 310, 311
  surgical indications and contraindications in, June, 328
  surgical management of, anesthesia in, June, 323
  treatment in, June, 235, 236
Potassium loading therapy, in management of Bartter's syndrome, June, 257
Pregnenolone, synthesis of, June, 180
Prostaglandins, urinary, Bartter's syndrome and, June, 255
Prostaglandins (*Continued*)
  urinary, therapeutic inhibition of, in management of Bartter's syndrome, June, 258
Pseudocysts, of adrenal gland, pathologic features of, June, 275
Pyelogram, intravenous, in diagnosis of adrenal lesions, June, 305
Pyelography, retrograde, ureteral injury and, Feb., 37, 52

RADIATION THERAPY, for nonseminomatous germ cell testicular carcinoma, in adults, Oct., 477–493
  techniques of, Oct., 483–486
  genital injury and, Feb., 156
  in adrenal neuroblastoma, June, 290
  in Cushing's disease, June, 222
  in management of testicular tumors, in children, Oct., 356
  prophylactic, of mediastinum and supraclavicular region, Oct., 487, 488
  "sandwich technique," results of, Oct., 488
Radiologic examination, in adrenal cysts, June, 276–279
  in adrenal lesions, June, 305–318
  in adrenal neuroblastoma, June, 289
  in Cushing's syndrome, June, 219, 220
  in metastatic pheochromocytoma, June, 248
  in primary aldosteronism, June, 233, 234
  urethral injury and, Feb., 83
Reimplantation, ureteral, Feb., 38, 39
Renal. See also *Kidney*.
  capsule flap, ureteral injury and, Feb., 45–49
  failure, in postoperatively nonfunctioning kidney, management of, Oct., 448
  function defects, Bartter's syndrome and, June, 253
  pedicle, injuries to, Feb., 9, 10
Renin, release of, June, 186
RNA tumor viruses, action of, Oct., 533, 534
Roentgen examination. See names of specific procedures.

SALT WASTING, fetal virilization and, June, 198, 199
"Sandwich technique" of radiation therapy, results of, Oct., 488
Sarcomas, testicular, in children, management of, Oct., 350, 351
Scanning, radionuclide, in diagnosis of adrenal lesions, June, 308
Seminoma, anaplastic, pathology of, Oct., 382
  cells of, culture of, Oct., 530, 531
  classic, pathology of, Oct., 360–363, 381
  clinical evaluation of, Oct., 384–386
  clinical staging of, Oct., 386
  etiology and staging of, Oct., 379–392
  prognosis of, Oct., 391

Seminoma (*Continued*)
role of elevated alpha-fetoprotein levels in, Oct., 400, 401
spermatocytic, pathology of, Oct., 363, 364, 383
symptoms of, Oct., 384
treatment of, Oct., 387–389
trophoblastic, pathology of, Oct., 382
Sexual function, after retroperitoneal lymphadenectomy, Oct., 523–528
Sexual infantilism, etiology of, June 207
Sphincter, urethral, injury to, Feb., 113
Spironolactone therapy, in Bartter's syndrome, June, 257
in primary aldosteronism, June, 235
Steroid hormones, mechanism of action of, June, 187, 188
Steroid studies, in diagnosis of Cushing's syndrome, June, 216, 217
cautions in, June, 219
Steroids, adrenal, biosynthesis of, June, 180, 193–195
nomenclature of, June, 179, 180
Sympathogonioma, adrenal, surgical indications and contraindications in, June, 329

TERA I, development and culture of, Oct., 531
Tera II, development and culture of, Oct., 531, 532
Teratocarcinoma, cells of, culture of, Oct., 530, 531
management of, in children, Oct., 350
pathology of, Oct., 369
Teratoma, benign, in children, findings in, Oct., 350
pathology of, Oct., 367–369
Testicular carcinoma, cells of, culture of, Oct., 529–536
clinical presentation of, Oct., 428, 429
diagnosis of, Oct., 428–433
management of patients with, Oct., 427–451
nonseminomatous, radiation therapy for, in adults, Oct., 477–493
surgical treatment of, in adults, Oct., 453–463
Testicular mass, surgical evaluation of, Oct., 433–435
Testicular tumors, advanced nonseminomatous, surgical management of, Oct., 465–476
biology of, Oct., 495–507
Testis, maldescent of, pathology of, Oct., 364, 365
tumor developing from, Oct., 440, 441
tumors in, in infants and children, Oct., 347–358
Testosterone, role of, in development of genitalia, June, 195
Thoracoabdominal approach, modified, in treatment of massive retroperitoneal tumors, technique of, Oct., 469–473
Tomography, computerized axial, in diagnosis of adrenal lesions, June, 308, 309
Toxicity, of chemotherapy, for testicular tumors, Oct., 490
Transureteroureterostomy, Feb., 39–42
Trauma, electrical, renal artery and, Feb., 13–16
to bladder, Feb., 59–67
to kidneys, Feb., 3–12, 17–28
to ureter, Feb., 33–44, 45–49, 51–57
to urethra, anterior, Feb., 125–162
posterior, Feb., 69–125
Tumors. See also specific tumors, e.g., *Carcinoma*.
adrenal, preoperative localization of, June, 219, 220, 241–243
radiologic studies in, June, 311
treatment of, June, 220, 221
adrenocortical, Cushing's syndrome and, June, 211, 212
surgical indications and contraindications in, June, 328
extra-adrenal, pathologic findings in, June, 235
malignant, of adrenal gland, surgical indications and contraindications in, June, 330
metastatic, to adrenal gland, clinical features of, June, 269, 270
surgical indications and contraindications in, June, 330
nonfunctioning, of adrenal gland, laboratory findings in, June, 264
pathologic findings in, June, 264
radiologic studies in, June, 315, 316
signs and symptoms of, June, 263
treatment in, June, 265
testicular. See specific name of tumor (*Seminoma, Nonseminomatous germ cell*, etc.).
Tyrosine, conversion of, June, 189

ULTRASONOGRAPHY, in diagnosis of adrenal cysts, June, 276
in diagnosis of adrenal lesions, June, 308, 309
Ureter, injuries to, Feb., 33–44, 45–49, 51–57
Ureteropelvic junction, repair of, Feb., 45–49
Urethra, anterior, injuries to, Feb., 125–131, 133–141, 143–156, 157–162
injuries to, pelvic fracture and, Feb., 81–93
posterior, injury to, Feb., 69–73, 75–80
strictures of, Feb., 95–104, 105–110, 111–124
Urethrography, retrograde, posterior urethral strictures and, Feb., 99
Urinary tract, anomalies of, congenital adrenal hyperplasia and, June, 207, 208
Urogenital diaphragm, posterior urethral strictures superior to, Feb., 95–104
Urography, excretory, ureteral injury and, Feb., 36, 37, 40, 41, 44

VAGINOPLASTY, in 21-hydroxylase deficiency, June, 204
Veins, adrenal, surgical anatomy of, June, 172
Venography, in adrenal cysts, June, 277
in adrenal lesions, June, 307, 308
in primary aldosteronism, June, 233
Vinblastine, in treatment of disseminated testicular carcinoma, Oct., 416
Virilization, fetal, classification of, June, 197, 198
Virus, role of, in human cancers, Oct., 533, 534

X-RAY. See *Radiation* and *Radiologic*.

YOLK SAC TUMOR, pathology of, Oct., 371–373

ZONA FASCICULATA, embryologic development of, June, 169
histologic anatomy of, June, 176
in hormone synthesis, June, 181
Zona glomerulosa, embryologic development of, June, 169
histologic anatomy of, June, 175
in aldosterone secretion, June, 187
in hormone synthesis, June, 182
Zona reticularis, embryologic development of, June, 169
histologic anatomy of, June, 176
in hormone synthesis, June, 181
Zuckerkandl, organ of, embryologic development of, June, 170